Rituximab and low dose oral immune modulating treatment to maintain a sustained response in severe pemphigus patients
Objectives: This pilot retrospective study examined the role of continuous low-dose maintenance immunomodulatory treatment (IMT) as an adjunct to rituximab (RTX) rescue therapy in severe pemphigus vulgaris (PV) and pemphigus foliaceus (PF) after a complete response (CR) to RTX was achieved. Material...
Main Authors: | Jordan M. Keeley, Stephanie L. Bevans, Tarannum Jaleel, Naveed Sami |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2019-05-01
|
Series: | Journal of Dermatological Treatment |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/09546634.2018.1510173 |
Similar Items
-
Rituximab/IVIG in pemphigus – a 10-year study with a long follow-up
by: Issam Hamadah, et al.
Published: (2019-02-01) -
Novel use of dupilumab in pemphigus vulgaris and pemphigus foliaceus
by: Christina Jiang, BS, MS, et al.
Published: (2023-12-01) -
An Updated Review of Pemphigus Diseases
by: Ali M. Malik, et al.
Published: (2021-10-01) -
Simultaneous endemic pemphigus foliaceus and psoriasis
vulgaris in Peru – immunogenetic or environmental factors?
by: Willy Ramos, et al.
Published: (2021-06-01) -
Successful treatment of recalcitrant juvenile pemphigus foliaceus with intravenous immunoglobulin and rituximab
by: Hock Gin Teo, et al.
Published: (2022-01-01)